A cinnamic acid derivative, its preparation method and application

By designing amide condensation compounds with cinnamic acid and phenothiazine skeletons, the limited therapeutic effect of APAP-induced liver injury in the severe stage was solved, achieving multi-target inhibition of oxidative damage, ferroptosis and inflammatory pathways, and significantly improving the therapeutic effect of liver injury.

CN123106579APending Publication Date: 2026-11-17YANAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611430461.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-15
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing drugs for treating APAP-induced liver injury have limited efficacy in severe stages and lack multi-target treatment strategies targeting ferroptosis and uncontrolled inflammation.

Method used

A cinnamic acid derivative was designed to link cinnamic acid with a phenothiazine skeleton via an amide condensation reaction, forming a novel hybrid molecule with synergistic anti-inflammatory and antioxidant effects, which can intervene in oxidative damage, ferroptosis, and inflammatory pathways.

Benefits of technology

It effectively inhibits APAP-induced lipid peroxidation in liver tissue, restores antioxidant capacity, regulates iron ion homeostasis, inhibits the release of inflammatory factors, breaks the vicious cycle of pathology, and exhibits good anti-inflammatory activity and in vivo tolerance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106579A_ABST
    Figure CN123106579A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology related to the treatment of acute liver injury (AILI), specifically relating to a cinnamic acid derivative, its preparation method, and its applications. Based on a fragment-linked molecular hybridization strategy, this invention selects phenylpropanoid natural acids with definite hepatoprotective activity as an anti-inflammatory lead scaffold. These compounds share a phenylpropionic acid core and can downregulate the expression of pro-inflammatory factors such as TNF-α and IL-6. Simultaneously, a phenothiazine scaffold with excellent antioxidant properties is introduced as a ferroptosis regulatory fragment, which can precisely combat the core driving force of lipid peroxidation by directly neutralizing free radicals and upregulating the endogenous antioxidant system. The two pharmacophores are covalently linked by ester bonds, aiming to construct a novel hybrid molecule with synergistic anti-inflammatory and antioxidant effects. The goal is to achieve simultaneous multi-target inhibition of inflammatory signals and the ferroptosis pathway in a single entity, thereby providing an innovative strategy for breaking the vicious cycle of AILI and developing highly effective and low-toxicity therapeutic lead compounds.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology for treating acute liver injury, specifically relating to a cinnamic acid derivative, its preparation method, and its application. Background Technology

[0002] Acute liver injury (ALI) refers to a clinical condition in which liver function rapidly deteriorates within two weeks after direct or indirect exposure to various liver-damaging risk factors in individuals with no pre-existing liver disease or those with stable liver disease. Drug-induced liver injury is one of the most common causes of acute liver failure (ALF). Among the many substances that can cause drug-induced liver injury, acetaminophen (APAP) is one of the most commonly used antipyretic, analgesic, and anti-inflammatory drugs. Furthermore, APAP-induced liver injury (AILI) is the most common cause of ALF in the United States and Europe, accounting for over 50% of ALF cases. Moreover, in a significant proportion of patients, APAP hepatotoxicity occurs at doses slightly above the maximum recommended daily dose of 4g.

[0003] In APAP-induced acute liver injury, the highly active intermediate NAPQI, produced by APAP metabolism via cytochrome P450, depletes intracellular glutathione (GSH) in large quantities. This not only directly induces oxidative stress and mitochondrial dysfunction but also inactivates glutathione peroxidase 4 (GPX4). GPX4 then catalyzes membrane phospholipid peroxidation via the Fenton reaction of free iron, thereby initiating ferroptosis. Simultaneously, damage-associated molecular patterns (DAMPs) and pro-inflammatory lipid peroxidation products released from massive hepatocyte necrosis and ferroptosis are recognized by immune receptors such as Kupffer cells, strongly activating the NF-κB and NLRP3 inflammasome pathways. This leads to a burst of release of pro-inflammatory factors such as TNF-α and IL-1β, and recruits neutrophils for infiltration, delivering a "second attack" on the remaining hepatocytes. More importantly, a vicious cycle of positive feedback exists between ferroptosis and inflammation: the iron ions and oxidized phospholipids specifically released by ferroptosis further exacerbate inflammatory signals, while the high levels of reactive oxygen species (ROS) and cytokines in the inflammatory microenvironment conversely deplete antioxidant reserves, inhibit GPX4 activity, and expand the free iron pool, leading to more hepatocytes undergoing lipid peroxidation and ferroptosis. This reinforcing loop of "ferroptosis-inflammation-exacerbated ferroptosis" is the core driving mechanism by which AILI progresses from localized damage to widespread liver necrosis and even acute liver failure.

[0004] Currently, clinical treatment for APAP poisoning mainly relies on the specific antidote N-acetylcysteine ​​(NAC) used in the early stages to supplement glutathione (GSH). However, for liver damage that has progressed to a severe stage, the therapeutic effect of the above-mentioned drugs is limited, and there is a lack of multi-target treatment strategies that target the complex downstream pathological networks (such as ferroptosis and uncontrolled inflammation). Summary of the Invention

[0005] To address the limited efficacy of existing drugs for treating APAP-induced liver injury in severe stages, this invention provides a cinnamic acid derivative, its preparation method, and its applications. This invention aims to explore and design novel compounds capable of simultaneously intervening in oxidative damage, ferroptosis, and inflammatory pathways, which has significant scientific value and application potential for expanding the prospects of drug treatment for liver injury. To achieve the above objectives, the technical solution of this invention is as follows.

[0006] This invention provides a cinnamic acid derivative, the general structural formula of which is as follows: Wherein, R is a C1-C3 alkyl group or a C4-C6 cycloalkyl group.

[0007] Preferably, the cinnamic acid derivative is any one of the following compounds: .

[0008] This invention provides a method for preparing a cinnamic acid derivative, comprising the following steps: Compound i was amidated with 2-aminomethylphenthiazide in an organic solvent in the presence of a phosphorus salt coupling agent and an organic base to prepare compound ii; compound ii was then amidated with cinnamic acid in an organic solvent in the presence of a phosphorus salt coupling agent and an organic base to prepare a cinnamic acid derivative; the chemical reaction formulas are as follows: .

[0009] Preferably, in the preparation of compound ii, the molar ratio of 2-aminomethylphenthiazide to compound i is 1 to 1.3:1; the molar ratio of compound i to the phosphonium salt coupling reagent and the organic base is 1:1 to 1.1:1.5 to 2.

[0010] Preferably, in the preparation of the cinnamic acid derivative, the molar ratio of compound i to cinnamic acid is 1:1; the molar ratio of cinnamic acid to the phosphorus salt coupling reagent and the organic base is 1:1 to 1.1:1.5 to 2.

[0011] Preferably, the phosphorus salt coupling agent is benzotriazol-1-yl-oxytripyrrolylphosphine hexafluorophosphate; the organic base is N,N-diisopropylethylamine; and the organic solvent is N,N-dimethylformamide.

[0012] This invention provides the use of a cinnamic acid derivative or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the prevention or treatment of acute liver injury.

[0013] Preferably, the drug is used to intervene in any one or more of the oxidative damage, ferroptosis, and inflammatory pathways.

[0014] Preferably, the drug is used to improve acetaminophen-induced oxidative damage and inflammatory pathways.

[0015] Preferably, the drug is used to inhibit the secretion of interleukin-6, interleukin-1β, and tumor necrosis factor-α in the acetaminophen-induced inflammatory pathway.

[0016] Preferably, the drug is used to inhibit Erastin-induced ferroptosis.

[0017] Preferably, the drug inhibits Erastin-induced ferroptosis in HepG2 cells by upregulating GPX4 expression.

[0018] The beneficial effects of this invention are: 1. This invention utilizes a fragment-linked molecular hybridization strategy, selecting phenylpropanoid natural acids with definite hepatoprotective activity as the anti-inflammatory lead scaffold. These compounds share the phenylpropionic acid core, scavenging free radicals and downregulating the expression of pro-inflammatory factors such as TNF-α and IL-6 through phenolic hydroxyl groups. Simultaneously, a phenothiazine scaffold with excellent antioxidant properties is introduced as a ferroptosis regulatory fragment, which can precisely combat the core driving force of lipid peroxidation by directly neutralizing free radicals and upregulating the endogenous antioxidant system. The two pharmacophores are covalently linked by ester bonds to construct a novel hybrid molecule with synergistic anti-inflammatory and antioxidant effects. The aim is to achieve simultaneous multi-target inhibition of inflammatory signals and the ferroptosis pathway in a single entity, thus providing an innovative strategy for breaking the vicious cycle of AILI and developing highly effective and low-toxicity therapeutic lead compounds.

[0019] 2. This invention uses a compound obtained by amide condensation of cinnamic acid and phenothiazine as a lead compound, and introduces different linking chains between the cinnamic acid and phenothiazine skeletons. By designing the corresponding linking chains, the anti-inflammatory and anti-ferroptosis activities are improved. In particular, the introduction of cyclic linking chains, due to their conformational restriction, allows the two pharmacophores of cinnamic acid and phenothiazine to present a more favorable three-dimensional configuration, thereby enhancing target affinity and significantly improving anti-ferroptosis and anti-inflammatory activities.

[0020] 3. The cinnamic acid derivative of the present invention can effectively inhibit APAP-induced lipid peroxidation in liver tissue, restore antioxidant capacity, and regulate iron ion homeostasis, thereby inhibiting ferroptosis at the in vivo level. The cinnamic acid derivative of the present invention can effectively inhibit the release of APAP-induced inflammatory factors, exhibiting good anti-inflammatory activity in vivo, and possessing good in vitro safety and in vivo tolerability. Attached Figure Description

[0021] Figure 1 The figures show the dose-response curves for Erastin-induced ferroptosis in HepG2 cells and LPS-induced NO production in BV2 cells. In Figure A, Erastin-induced ferroptosis in HepG2 cells is the dose-response curve (n=5); and LPS-induced NO production in BV2 cells is the dose-response curve (n=5).

[0022] Figure 2 The results of antioxidant and iron chelating assays for compound LYL7 are presented. In this table, A represents the cell-free antioxidant potential monitored by relative DPPH uptake; B represents the chelating assay results for compound LYL7. Data are expressed as mean ± standard deviation (n = 3). ns indicates no significant difference; ***P < 0.001.

[0023] Figure 3 The levels of ferroptosis markers ROS, GSH, and MDA in the HepG2 cell ferroptosis model are shown. A represents the ROS level in the HepG2 cell ferroptosis model; B is a statistical graph of GSH level in the HepG2 cell ferroptosis model; C is a statistical graph of MDA level in the HepG2 cell ferroptosis model. Data are expressed as mean ± standard deviation (n = 3); ### indicates P < 0.001 compared to the control group; ns indicates no significant difference, indicating P < 0.01; * indicates P < 0.001 compared to cells treated with Erastin only; ^^ indicates P < 0.01, ^^^ indicates P < 0.001 compared to the LYL7 group in the Fer-1 group; scale bar = 20 μmol / L.

[0024] Figure 4Representative fluorescence images of intracellular reactive oxygen species (ROS) in different treatment groups are shown. Specifically, a1–a3 represent the fluorescence staining results of ROS in the normal group (control group) (a1 is the ROS fluorescence channel; a2 is the bright field; a3 is the merged image); b1–b3 represent the fluorescence staining results of ROS in the Erastin group; c1–c3 represent the fluorescence staining results of ROS in the DMSO group; d1–d3 represent the fluorescence staining results of ROS in the cinnamic acid group; e1–e3 represent the fluorescence staining results of ROS in the Fer-1 group; f1–f3 represent the fluorescence staining results of ROS in the LYL7 (1 μm) group; g1–g3 represent the fluorescence staining results of ROS in the LYL7 (0.1 μm) group; and h1–h3 represent the fluorescence staining results of ROS in the LYL7 (0.01 μm) group.

[0025] Figure 5 Fe, a biomarker of ferroptosis in the HepG2 cell ferroptosis model 2+ Content. Data are expressed as mean ± standard deviation (n = 3). ### indicates P < 0.001 compared with control cells. ns indicates not significant, * indicates P < 0.01, * indicates P < 0.001 compared with cells treated with Erastin only; ^^ indicates P < 0.01 compared with Fer-1 group compared with LYL7 group.

[0026] Figure 6 This study investigated the expression levels and statistical analysis of GPX4 and xCT proteins in a HepG2 cell ferroptosis model. In the figures, A represents the expression levels of GPX4 and xCT proteins in HepG2 cells; B is a statistical graph of GPX4 protein expression in HepG2 cells; and C is a statistical graph of xCT protein expression in HepG2 cells. Data are expressed as mean ± standard deviation (n = 3). *** indicates P < 0.001 compared to Erasin-treated cells; ### indicates P < 0.001; ## indicates P < 0.01 compared to Erasin-treated cells; ns indicates no significant difference.

[0027] Figure 7 The expression levels of IL-6, TNF-α, and IL-1β in a BV2 cell inflammation model are shown. In the figure, A represents the statistical graph of IL-6 protein expression in BV2 cells; B represents the statistical graph of IL-1β protein expression in BV2 cells; and C represents the statistical graph of TNF-α protein expression in BV2 cells. Data are expressed as mean ± standard deviation (n = 3). ### indicates P < 0.001 compared to the control group. * indicates P < 0.01, * indicates P < 0.001 compared to cells treated with Erastin only; ^ indicates P < 0.05, and ^^ indicates P < 0.01 compared to cells treated with Erastin LYL7.

[0028] Figure 8 HE staining images of liver tissue sections from mice after liver injury in each group. Among them, a1 is the normal group; a2 is the APAP group; a3 is the cinnamic acid group; a4 is the NAC group; a5 is the Fer-1 group; and a6 is the LYL7 group.

[0029] Figure 9 The values ​​represent liver function biochemical indicators in the serum of mice in each group. A represents GPT content; B represents GOT content. Data are expressed as mean ± standard deviation (n=3). *** indicates P < 0.001 compared to the APAP group. ## indicates P < 0.01, ### indicates P < 0.001 compared to the LYL7 group. Scale bar = 20 μmol / L.

[0030] Figure 10 The levels of MDA, GSH, and Fe in the liver tissue of mice in each group after liver injury were measured. 2+ Content. Where A represents MDA content; B represents GSH content; C represents Fe content. 2+ Content. Data are expressed as mean ± standard deviation (n = 3). Compared with the APAP group, *P<0.05, P<0.01, *P<0.001; compared with the LYL7 group, #P<0.05, ##P<0.01, ###P<0.001; ns indicates no statistically significant difference.

[0031] Figure 11 The expression levels of IL-6, IL-1β, and TNF-α in the liver tissue of mice in each group after liver injury are shown. A represents IL-6 content; B represents IL-1β content; and C represents TNF-α content. Data are expressed as mean ± standard deviation (n = 3). Compared with the APAP group, *P<0.05, P<0.01, *P<0.001; compared with the LYL7 group, #P<0.05, ##P<0.01, ###P<0.001; ns indicates no statistically significant difference.

[0032] Figure 12The results of cytotoxicity assays for compound LYL7 are shown below. Specifically, A represents the cytotoxicity assay results of compound LYL7 in BV2 cells; B represents the cytotoxicity assay results of compound LYL7 in HK-2 cells; C represents the cytotoxicity assay results of compound LYL7 in HepG2 cells; D represents the cytotoxicity assay results of compound LYL7 in PC12 cells; E represents the cytotoxicity assay results of compound LYL7 in HCT116 cells; F represents the cytotoxicity assay results of compound LYL7 in HPNE cells; G represents the cytotoxicity assay results of compound LYL7 in L02 cells; and H represents the cytotoxicity assay results of compound LYL7 in RKO cells. Data are expressed as mean ± standard deviation (n = 3). ns indicates no statistically significant difference; *P<0.05, P<0.01, *P<0.001.

[0033] Figure 13 Changes in body weight of mice in each group during drug administration are shown. Data are expressed as mean ± standard deviation (n = 3). ns indicates no statistically significant difference.

[0034] Figure 14 The changes in serum biochemical indicators related to liver and kidney function in mice of each group are shown. A represents the serum GPT content of each group of mice; B represents the serum GOT content of each group of mice; C represents the serum Scr content of each group of mice; and D represents the serum BUN content of each group of mice. Data are expressed as mean ± standard deviation (n = 3). ns indicates no significance.

[0035] Figure 15 The effects of compound LYL7 on major organs and tissues in mice. Detailed Implementation

[0036] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are only for explaining the invention and are not intended to limit the invention. All other embodiments obtained by those skilled in the art based on the embodiments of this invention without creative effort are within the scope of protection of this invention. The technical solutions of this invention will be further described below through specific embodiments. In the following embodiments, unless otherwise specified, the methods are conventional methods; the reagents and materials, unless otherwise specified, are commercially available.

[0037] 1. Screening of natural acid skeletons.

[0038] 1.1 Design and Synthesis of Target Compounds: To investigate the influence of different phenolic acid structures on the dual pharmacological activities of target molecules and to screen for the optimal parent nucleus, this invention selected five structurally distinct natural phenylpropionic acids—cinnamic acid, caffeic acid, sinapic acid, coumaric acid, and ferulic acid—as starting modification targets. In molecular design, these natural acids were condensed with phenothiazine skeletons possessing antioxidant activity using a molecular hybridization strategy, resulting in the design and synthesis of a series of natural acid-phenothiazine hybrid molecules. The structural formulas of YL1–YL5 are as follows: .

[0039] Cinnamic acid (148.16 mg, 1.0 mmol), intermediate Y1 (1.1 mmol), PyBOP (1.1 mmol), and DIPEA (2.0 mmol) were added sequentially to a reaction flask, dissolved in anhydrous DMF, and the mixture was stirred at room temperature for 4 h. After the starting materials were completely consumed, the reaction solution was extracted with dichloromethane and saturated brine. The organic phases were combined, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified to obtain compound YL1. The synthesis of compounds YL2–YL5 was performed using the same method, except that cinnamic acid was replaced with caffeic acid, sinapic acid, coumaric acid, or ferulic acid. The structural formula of intermediate Y1 is as follows. .

[0040] Compound YL1: Yellowish-brown solid, 46% yield. 1 H NMR (400MHz, DMSO) δ 8.64 (s, 1H),8.61 (s, 1H), 7.59 (s, 1H), 7.57 (s,1H), 7.47 (s,1H), 7.46 - 7.35 (m, 3H),6.97 (s, 1H), 6.88 (d, J= 12.2 Hz, 2H), 6.74 (s, 1H), 6.72 (s, 1H), 6.68 (d,J = 7.8 Hz, 2H), 6.63 (s, 1H), 4.27 (d,J = 5.9 Hz, 2H). 13 C NMR (101MHz, DMSO-d6) 8 165.47, 142.72, 142.56,139.60,135.36,130.06, 129.50,128.07, 128.04,126.75, 126.62, 122.49, 122.28, 121.37, 116.92, 115.22,114.97, 113.79, 42.35.

[0041] Compound YL2: white solid, 42% yield. 1H NMR (400MHz, DMSO) δ 8.63 (s, 1H), 8.45 (s, 1H), 7.38 (d, J = 15.7 Hz, 1H), 7.13 (s, 1H), 7.01 (d, J = 8.2 Hz, 1H), 6.96 (s, 1H), 6.89 (s, 1H), 6.86 (d,J= 7.8 Hz 1H), 6.80 (d, J = 8.1 Hz, 1H), 6.73 (s, 1H), 6.69 (s, 1H), 6.67 (s, 1H), 6.62 (s, 1H), 6.51 (d,J= 15.7 Hz,1H), 4.24 (d, J = 5.9 Hz, 2H), 3.80 (s, 3H). 13 C NMR (101MHz, DMSO-d6) δ165.91, 148.85, 148.33, 142.68, 142.58, 139.96, 139.81, 128.04, 126.85,126.74, 126.58, 122.26, 122.04, 121.31, 119.22, 116.92, 116.19, 115.10,114.96, 113.74, 111.28, 56.01, 42.27.

[0042] Compound YL3: yellow solid, 45% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (s, 1H), 8.49 (s, 1H), 7.96 (s, 2H), 7.32 (d, J= 15.6 Hz, 1H), 6.98 (d, J = 4.3 Hz, 2H), 6.93-6.85 (m, 3H), 6.76 (d, J = 17.3 Hz, 2H), 6.69 (d, J = 7.9 Hz, 2H), 6.64 (s, 1H), 6.42 (d, J = 15.7 Hz, 1H), 4.26 (d, J = 5.9 Hz, 2H), 1.93 (s, 2H). 13CNMR (101MHz, DMSO-d6) δ 165.93, 162.85, 147.91, 146.08, 142.69, 142.57,140.10, 139.82, 128.04, 126.82, 126.73, 126.58, 122.26, 121.32, 121.07,118.71, 116.90, 116.28, 115.10, 114.96, 114.24, 113.72, 100.00.

[0043] Compound YL4: Pink solid, 49% yield. 1 H NMR (400MHz, DMSO) δ 8.83 (s, 1H), 8.62 (s, 1H), 8.43 (s, 1H), 7.38 (d, J = 15.7 Hz, 1H), 6.97 (s, 1H), 6.90 (d,J = 6.3 Hz, 1H), 6.86 (t, J= 3.9 Hz,3H), 6.73 (s, 1H), 6.68 (s, 1H), 6.66 (s,1H), 6.61 (s, 1H), 6.54 (d, J= 15.7 Hz, 1H), 4.24 (d, J= 5.9 Hz, 2H), 3.79(s, 1H). 13 C NMR (101MHz, DMSO-d6) δ 165.86, 148.57, 142.68, 142.58, 140.24,139.79, 137.84, 128.04, 126.74, 126.59, 122.27, 121.30, 119.66, 116.93,115.11, 114.96, 113.75, 105.70, 56.46, 42.30.

[0044] Compound YL5: yellow solid, 46% yield. 1 H NMR (400MHz, DMSO) δ 10.02 (s, 1H),8.69 (s, 1H), 8.13 (s, 1H), 7.50 (s, 1H), 6.99 (s, 1H), 6.92 (d, J = 7.8 Hz,2H), 6.75 (s, 1H), 6.73 (s, 1H), 6.70 (s, 1H), 6.59 (s, 1H), 5.56 (s, 1H), 4.50 (d, J = 6.1 Hz, 2H).13 C NMR (101MHz, DMSO-d6) δ 163.97, 162.64, 160.72,149.65, 142.89, 142.34, 137.50, 128.12, 126.94, 126.74, 122.42, 121.40,116.69, 116.33, 115.05, 113.70, 101.41, 93.50, 52.67.

[0045] 1.2 In vitro antiferroptosis activity assay: To evaluate the in vitro antiferroptosis activity of compounds YL1–YL5, an in vitro ferroptosis model was established using Erastin-induced HepG2 cells. Cell viability after 24 h of treatment with different concentrations of Erastin was determined using the CCK-8 assay, and the IC50 was obtained by fitting dose-response curves. 50 The concentration was 10 μmol / L, which was used as the subsequent modeling concentration. Figure 1 Figure A shows the dose-response curve (n=5) of Erastin-induced ferroptosis in HepG2 cells. Based on the established Erastin-induced ferroptosis model, the antiferroptosis activity of compounds YL1–YL5 was evaluated. The results showed that compounds YL1–YL5 could alleviate the Erastin-induced decrease in cell viability to some extent, but the protective effects differed significantly. Among them, compound YL1, synthesized by hybridization of cinnamic acid and phenothiazine, exhibited the strongest cytoprotective effect, with an EC50 of [missing value]. 50 The value was 0.067 μmol / L. In comparison, the other four phenolic acid derivatives showed weaker activity.

[0046] 1.3 In vitro anti-inflammatory activity assay: To evaluate the anti-inflammatory activity of compounds YL1–YL5, an in vitro inflammation model was established using LPS-induced BV2 cells. The IC50 of LPS treatment for 24 h was measured using the CCK-8 assay. 50 The concentration was 900 ng / mL, which was used as the modeling concentration. Figure 1 Figure B shows the dose-response curve for LPS-induced inflammatory cell death in BV2 cells (n=5). Based on the established LPS-induced inflammation model, the anti-inflammatory activity of compounds YL1–YL5 was evaluated. The results showed that compounds YL1–YL5 could alleviate LPS-induced inflammation to some extent, but the protective effects differed significantly. Among them, compound YL1, synthesized by hybridization of cinnamic acid and phenothiazine skeleton, and compound YL3, synthesized by hybridization of caffeic acid and phenothiazine skeleton, exhibited the strongest cytoprotective effects.

[0047] 1.4 Structure-Activity Relationship Analysis: A comparative analysis of the in vitro antiferroptosis and anti-inflammatory activities revealed that YL1 exhibited the best activity in antiferroptosis screening, while its anti-inflammatory activity was comparable to that of YL3. YL3 demonstrated outstanding anti-inflammatory activity, but its antiferroptosis activity was significantly weaker than that of YL1. The remaining three compounds showed only moderate performance in both evaluations. Based on the goal of synthesizing dual-target compounds, an ideal candidate molecule should possess the ability to simultaneously intervene in two targets. YL1 performed excellently in both activity evaluations, demonstrating a balanced dual regulatory potential. While YL3 exhibited excellent anti-inflammatory activity, its insufficient antiferroptosis activity may limit its overall protective effect against liver injury. Therefore, this invention identified cinnamic acid as the dominant host nucleus hybridized with the phenothiazine skeleton for subsequent structural optimization studies.

[0048] Table 1. Comparison of structure-activity relationships of compounds YL1 to YL5 compound <![CDATA[EC 50 (μmol / L)]]> NO inhibition rate (%) compound <![CDATA[EC 50 (μmol / L)]]> NO inhibition rate (%) YL1 0.067±0.05 78.68±0.03 YL4 0.283±0.02 39.93±0.05 YL2 0.189±0.04 28.65±0.02 YL5 0.195±0.04 28.69±0.03 YL3 0.245±0.03 76.92±0.04 / / / Note: EC 50 The concentration of the test compound required to rescue 50% of Erastin-induced cell death in HepG2 cells is indicated. The NO inhibition rate indicates the percentage of inhibition of nitric oxide (NO) production in LPS-induced BV2 microglia by the test compound. " / " indicates none.

[0049] 2. Substituent modification of cinnamic acid parent compound.

[0050] 2.1 Design and Synthesis of Target Compounds: Using YL1 as the parent compound, the benzene ring of its cinnamic acid was modified with substituents. The selection of substituents was primarily based on the following considerations: a) Electron-donating and electron-withdrawing effects: Electron-donating groups such as methyl and methoxy groups, and electron-withdrawing groups such as fluorine, chlorine, and cyano groups were introduced to examine the effect of changes in the electron cloud density of the benzene ring on the interaction between the molecule and the target; b) Hydrophobicity and steric hindrance: The introduction of methyl and methoxy groups can adjust the hydrophobic parameters of the molecule, while multiple substitutions can further examine the effect of steric hindrance on activity; c) Hydrogen bond donor capability: Phenolic hydroxyl groups were introduced to evaluate the contribution of hydrogen bond donors to activity, especially considering the excellent anti-inflammatory activity of the previous caffeic acid derivative YL3 due to its ortho-diphenolic hydroxyl group; d) Halogen substitution: Halogen atoms such as fluorine and chlorine, due to their moderate electronegativity and hydrophobicity, are often used in drug structure optimization to improve metabolic stability and target affinity. Based on the above design ideas, cinnamic acid derivatives with different substitution modes were selected. Following the synthetic method of YL1, the above-mentioned substituted cinnamic acid was subjected to amide condensation reaction with the phenothiazine skeleton to synthesize a total of 22 target compounds: YL6 to YL27.

[0051] .

[0052] Compound YL6: yellow solid, 44% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (d, J = 3.9Hz, 2H), 7.72 (s, 1H), 7.52 (s, 1H), 7.29-7.21 (m, 3H), 6.97 (s, 1H), 6.87(d, J = 7.8 Hz, 2H), 6.76-6.65(m, 3H), 6.64 (s, 1H), 6.59 (d, J = 15.7 Hz, 1H), 4.26 (d, J = 5.9 Hz, 2H), 2.38 (s, 3H). 13 C NMR (101MHz, DMSO-d6) δ165.85, 158.07, 142.70, 142.59, 139.71, 134.62, 131.41, 128.40, 128.03,126.72, 126.57, 123.74, 122.92, 122.25, 121.36, 121.24, 116.89, 115.14,114.97, 113.80, 112.20, 56.06, 42.32.

[0053] Compound YL7: yellow solid, 50% yield. 1 H NMR (400MHz, DMSO) δ 8.78 (s, 1H), 8.72(s, 1H), 7.56 (s, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.45 (s, 1H), 7.35 (s, 1H), 7.11 (s, 1H), 7.01 (d, J = 7.8 Hz, 2H), 6.88 (s, 1H), 6.83 (d, J= 5.4 Hz,2H), 6.80 (s, 1H), 6.77 (s, 1H), 4.40 (d, J = 6.0 Hz, 2H), 2.47 (s, 3H). 13CNMR (101MHz, DMSO-d6) 8 165.52, 142.72, 142.58, 139.68, 139.62, 138.65,135.32, 130.76, 129.38, 128.65, 128.03, 126.74, 126.61, 125.21, 122.35,122.27, 121.36, 116.94, 115.24, 114.97, 113.81, 42.36, 21.46.

[0054] Compound YL8: brown solid, 47% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (s, 1H), 8.55(s, 1H), 7.48- 7.41 (m, 3H), 7.23 (d, J = 8.0 Hz, 2H), 6.97 (s, 1H), 6.87 (d,J = 14.2 Hz, 2H), 6.74 (s, 1H), 6.66 (dd, J = 22.2, 10.6 Hz, 4H), 4.26 (s,2H), 2.32 (s, 3H). 13 C NMR (101MHz, DMSO-d6) 8 165.60, 142.71, 142.57, 139.80,139.67, 139.54, 132.61, 130.10, 128.04, 126.74, 126.60, 122.27, 121.45,121.35, 116.92, 115.19, 114.96, 113.76, 42.31, 21.49.

[0055] Compound YL9: yellow solid, 42% yield. 1 H NMR (400MHz, DMSO) δ 8.62 (s, 1H), 8.57(s, 1H), 7.64 (d, J = 15.7 Hz, 1H), 7.40 (d, J = 8.3 Hz, 1H), 7.01 (d, J =7.2 Hz, 2H), 6.93 (s, 1H), 6.83 (d, J = 13.1 Hz, 2H), 6.72 -6.62 (m, 3H),6.61 (s, 1H), 6.52 (d, J = 15.7 Hz, 1H), 4.22 (d, J=5.9 Hz2H), 2.30 (s, 3H),2.23 (s, 3H).13 C NMR (101MHz, DMSO-d6) 8 165.64, 142.71, 142.57, 139.66,139.40, 137.20, 136.86, 131.90, 131.28, 128.04, 127.64, 126.74, 122.53,122.27, 121.40, 116.71, 115.21, 114.96, 113.84, 42.35, 21.35, 19.91.

[0056] Compound YL10: white solid, 45% yield. 1 H NMR (400MHz, DMSO) δ 8.61 (s, 1H),8.57 (s, 1H), 7.64 (d, J = 15.7 Hz, 1H), 7.31 (s, 1H), 7.08 (d, J = 7.8 Hz,1H), 7.04 (d, J = 7.8 Hz, 1H), 6.93 (s, 1H), 6.84 (d, J = 12.4 Hz, 2H), 6.70(s, 1H), 6.66 (d, J = 7.1 Hz, 2H), 6.59 (d, J = 12.7 Hz, 2H), 4.23 (d, J= 5.9Hz, 2H), 2.28 (s, 3H), 2.24 (s, 3H). 13 C NMR (101MHz, DMSO-d6) 8 165.54,142.71, 142.57, 139.62, 137.05, 135.76, 134.26.133.92.131.19, 130.54,128.05.126.83, 126.75, 126.62, 123.39, 122.28, 121.40, 116.91, 115.23,114.96, 113.86, 42.37, 21.13, 19.50.

[0057] Compound YL11: yellow solid, 44% yield. 1H NMR (400MHz, DMSO) δ 10.19 (s, 1H), 8.69 (s, 1H), 8.61 (s, 1H), 7.68 (d, J = 15.9 Hz, 1H), 7.42 (d, J= 6.2 Hz, 1H), 7.18 (s, 1H), 6.97 (s, 1H), 6.95 (s, 1H), 6.92 (d, J = 9.3 Hz, 1H), 6.87(s, 1H), 6.85 (s, 1H), 6.76 (s, 1H), 6.72 (s, 1H), 6.70 (d, J= 7.9Hz, 2H), 6.64 (s, 1H), 4.24 (d, J= 6.0 Hz, 2H). 13 C NMR(101MHz, DMSO-d6) 8 166.22,157.00, 142.71, 142.64, 139.82, 135.55, 135.55, 130.97, 128.78, 127.99,126.70, 126.54, 122.21, 121.29, 119.77, 116.90, 116.73, 115.01, 113.79.

[0058] Compound YL12: brown solid, 42% yield. 1 H NMR (400MHz, DMSO) 8 9.93 (s, 1H),8.66 (s, 1H), 8.50 (s, 1H), 7.45 - 7.33 (m, 3H), 6.97 (s, 1H), 6.87 (d, J =15.9 Hz, 2H), 6.81 (d, J = 8.6 Hz, 2H), 6.73 (s, 1H), 6.68 (d, J = 7.8 Hz,1H), 6.62 (s, 1H), 6.48 (d, J = 15.8 Hz, 1H), 4.24 (d, J=5.9 Hz 2H). 13 C NMR(101MHz, DMSO-d6) 8 165.98, 159.53, 142.71, 142.61, 139.81, 139.68, 129.76,128.01, 126.71, 126.56, 126.31, 122.23, 121.30, 118.93, 116.91, 116.34,115.08, 114.99, 113.76, 42.27.

[0059] Compound YL13: yellow solid, 46% yield. 1 H NMR (400MHz, DMSO) δ 9.64 (s, 1H), 8.63 (d, J = 13.8 Hz, 2H), 7.39 (d, J = 15.7 Hz, 1H), 7.21 (s, 1H), 7.00 (s, 1H), 6.98 (s, 1H), 6.95 (s, 1H), 6.88 (d, J= 13.3 Hz, 2H), 6.80 (d, J = 8.0Hz, 1H), 6.74 (s, 1H), 6.68 (d, J = 7.9 Hz, 2H), 6.62 (d, J= 15.4 Hz 2H), 4.26 (d, J = 5.9 Hz, 2H). 13 C NMR (101MHz, DMSO-d6) 8 165.49, 158.25, 142.72,142.57, 139.79, 139.61, 136.62, 130.50, 128.04, 126.74, 126.61, 122.27,122.23, 121.37, 119.31, 117.30, 116.90, 115.19, 114.97, 114.16, 113.76,42.31.

[0060] Compound YL14: gray solid, 47% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (s, 1H),8.58 (s, 1H), 7.71 (d, J = 15.9 Hz, 1H), 7.52 (d, J = 6.2 Hz, 1H), 7.37 (s,1H), 7.08 (d, J = 8.2 Hz, 1H), 6.98 (d, J= 7.6 Hz, 2H), 6.88 (d, J = 14.3 Hz,2H), 6.69 (dd, J = 17.3, 11.4 Hz, 4H), 6.62 (s, 1H), 4.25 (d, J = 5.9 Hz,2H), 3.86 (s, 1H). 13C NMR (101MHz, DMSO-d6) 8 165.83, 158.08, 142.69, 142.56,139.71, 134.66, 131.42, 128.42, 128.04, 126.73, 126.59, 123.73, 122.89,122.27, 121.37, 121.24, 116.90, 115.15, 114.95, 113.79, 112.21, 56.07, 42.32.

[0061] Compound YL15: Pink solid, 47% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (s, 1H),8.51 (s, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.43 (d, J = 15.8 Hz, 1H), 6.97 (t, J= 8.4 Hz, 3H), 6.89 (s, 1H), 6.86 (s, 1H), 6.74 (s, 1H), 6.68 (d, J = 7.9 Hz, 2H), 6.62 (s, 1H), 6.55 (d, J= 15.8 Hz, 1H), 4.25 (d, J = 5.9 Hz, 2H), 3.79(s, 3H). 13 C NMR(101MHz, DMSO-d6) 8 165.76, 160.87, 142.69, 142.57, 139.75,139.28, 129.64, 128.03, 127.92, 126.74, 126.59, 122.26, 121.33, 120.00,116.92, 115.14, 114.93, 113.75, 55.77, 42.29.

[0062] Compound YL16: Bright pink solid, 47% yield. 1H NMR (400MHz, DMSO) δ 8.64 (s, 1H),8.56 (s, 1H), 7.41 (d, J = 15.8 Hz, 1H), 6.98 (s, 1H), 6.89 (d, J = 13.4 Hz,2H), 6.78 - 6.74 (m, 3H), 6.72 (s, 1H), 6.69 (d, J = 5.3 Hz, 2H), 6.64 (s,1H), 6.54 (s, 1H), 4.27 (d, J = 5.9 Hz, 2H), 3.78 (s, 6H). 13 C NMR(101MHz,DMSO-d6) 8 165.45, 161.23, 142.68, 142.53, 139.62, 139.52, 137.34, 128.06,126.75, 126.63, 123.04, 122.32, 121.37, 116.89, 115.22, 114.96, 113.78,105.95, 102.03, 55.79, 42.35.

[0063] Compound YL17: pink solid, 46% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (d, J = 5.1Hz, 2H), 7.68 (d, J= 15.9 Hz, 1H), 7.14 (s, 1H), 7.10 (d, J = 9.7 Hz, 2H), 6.97 (s, 1H), 6.88 (d, J = 12.8 Hz, 2H), 6.76 - 6.63 (m, 5H), 4.26 (d, J =5.9 Hz, 2H), 3.82 (s, 3H), 3.75 (s, 3H). 13 C NMR(101MHz, DMSO-d6) δ 165.66,153.36, 147.88, 142.70, 142.53, 139.57, 134.07, 128.89, 128.05, 126.75,126.63, 124.97, 123.56, 122.31, 121.43, 118.96, 116.89, 115.24, 114.96,114.30, 113.84, 61.20, 56.23, 42.37.

[0064] Compound YL18: Bright yellow solid, 40% yield.1 H NMR (400MHz, DMSO) δ 8.73 (s, 1H), 8.65 (s, 1H), 7.67 (s, 1H), 7.55 (d, J = 16.0 Hz, 1H), 7.43 (s, 1H), 7.28 (d,J = 7.9 Hz, 2H), 6.97 (s, 1H), 6.88 (d, J = 12.8 Hz, 2H), 6.80 (d, J = 15.9Hz, 1H), 6.77 -6.66 (m, 3H), 6.64 (s, 1H), 4.27 (d, J= 5.9 Hz, 2H). 13 C NMR(101MHz, DMSO-d6) 8 165.38, 164.46, 162.00, 142.71, 142.56, 139.59, 138.39,130.27, 130.19, 128.04, 126.74, 126.61, 122.39, 122.28, 121.36, 116.90,116.59, 116.37, 115.20, 114.96, 113.77, 42.33.

[0065] Compound YL19: yellow solid, 42% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (d, J = 9.8Hz, 2H), 7.47 (dd, J = 26.3, 11.6 Hz, 4H), 7.22 (s, 1H), 6.98 (s, 1H), 6.88(d, J = 12.1 Hz, 2H), 6.78 - 6.62 (m, 5H), 4.28 (d, J = 5.9 Hz, 2H). 13 C NMR(101MHz, DMSO-d6) 8 165.16, 164.20, 161.78, 142.71, 142.55, 139.50, 138.28,131.41, 128.04, 126.74, 124.18, 124.07, 122.28, 121.38, 116.91, 116.61,115.25, 114.96, 114.62, 114.41, 113.80, 42.39.

[0066] Compound YL20: Bright yellow solid, 49% yield. 1H NMR (400MHz, DMSO) δ 8.63 (s, 1H),8.59 (s, 1H), 7.65 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 15.8 Hz, 1H), 7.25 (d, J= 8.9 Hz, 2H), 6.97 (s, 1H), 6.88 (d, J= 13.4 Hz, 2H), 6.74 (s, 1H), 6.70 (s,1H), 6.68 (s, 1H), 6.66 (s, 1H), 6.62(s, 1H), 4.26 (d, J=5.9Hz, 2H). 13 C NMR(101MHz, DMSO-d6) 8 165.43, 162.01, 142.74, 142.58, 139.58, 138.41, 132.02,130.25, 128.01, 126.73, 126.61, 122.26, 121.36, 116.96, 116.56, 116.34,115.27, 114.98, 113.81, 42.38.

[0067] Compound YL21: brown solid, 41% yield. 1 H NMR (400MHz, DMSO) δ 8.62 (d, J = 9.4Hz, 2H), 7.70 (s, 1H), 7.51 (s, 1H), 7.46 (d, J = 15.6 Hz, 2H), 6.97 (s, 1H), 6.88 (d, J = 13.4 Hz, 2H), 6.74 (s, 1H), 6.69 (s, 1H), 6.68 (s, 1H), 6.65 (s,1H), 6.62 (s, 1H), 4.26 (d, J = 5.9 Hz, 2H). 13 C NMR (101MHz, DMSO-d6) 8166.16, 165.13, 156.96, 142.69, 142.62, 139.84, 139.50, 135.52, 130.97,128.78, 128.00, 126.70, 122.22, 121.98, 121.30, 119.78, 116.89, 116.68,114.99, 113.77.

[0068] Compound YL22: white solid, 49% yield. 1H NMR (400MHz, DMSO) δ 8.64 (s, 2H), 7.47 (d, J= 15.8 Hz, 1H), 7.38-7.24 (m, 3H), 6.98 (s, 1H), 6.88 (d, J= 12.6Hz, 2H), 6.77 (d, J= 15.9 Hz, 2H), 6.69 (d, J = 6.0 Hz, 2H), 6.62 (s, 1H), 4.26 (d, J = 5.9 Hz, 2H). 13 C NMR (101MHz, DMSO-d6) 8 165.10, 142.71, 142.55,139.50, 137.48, 128.04, 126.74, 126.61, 125.18, 123.88, 122.27, 121.36,118.68, 118.51, 116.90, 116.76, 115.24, 114.96, 113.79, 42.38.

[0069] Compound YL23: white solid, 44% yield. 1 H NMR (400MHz, DMSO) δ 8.69 (s, 1H),8.61 (s, 1H), 7.75 (d, J = 15.8 Hz, 1H), 7.68 (s, 1H), 7.48 (s, 1H), 7.37 (d,J = 9.4 Hz, 2H), 6.93 (s, 1H), 6.83 (d, J= 7.8 Hz, 2H), 6.73 (s, 1H), 6.68(d, J = 6.1 Hz 2H), 6.62 (d, J = 16.7 Hz, 2H), 4.23 (d, J =5.9 Hz, 2H). 13 C NMR(101MHz, DMSO-d6) 8 164.94, 142.73, 142.54, 139.43, 134.88, 133.86, 133.13,131.52, 130.55, 128.35.128.05, 126.74, 126.63, 125.52, 122.28, 121.45,116.88, 115.31, 114.96, 113.87, 42.44.

[0070] Compound YL24: yellow solid, 46% yield. 1H NMR (400MHz, DMSO) δ 8.59 (d, J = 9.9Hz 2H), 7.61 (s, 1H), 7.51 (s, 1H), 7.46-7.37 (m, 3H), 6.93 (s, 1H), 6.83 (d,J = 12.2 Hz, 2H), 6.68 (dd, J = 29.8, 11.9 Hz, 4H), 6.59 (s, 1H), 4.23 (d, J= 5.9 Hz, 2H). 13 C NMR(101MHz, DMSO-d6) 8 165.11, 142.72, 142.55, 139.47,138.04, 137.69, 134.22, 131.32, 129.68, 128.05, 127.82, 126.75, 126.63,126.48, 124.18, 122.29, 121.38, 116.90, 115.26, 114.97, 113.80, 42.38.

[0071] Compound YL25: Bright yellow solid, 49% yield. 1 H NMR (400MHz, DMSO) δ 9.94 (s, 1H),8.59 (s, 1H), 8.37 (s, 1H), 7.54 (d, J = 15.8 Hz, 1H), 7.19 (d, J = 8.5 Hz,1H), 6.92 (s, 1H), 6.85 (s, 1H), 6.81 (d, J= 7.8 Hz, 1H), 6.69 (s), 6.63 (d,J= 8.0 Hz), 6.57 (s), 6.48 (d, J = 15.8 Hz), 6.31 (s), 6.22 (d, J= 8.4 Hz), 4.18 (d, J = 5.8 Hz). 13 C NMR(101MHz, DMSO-d6) 8 166.64, 160.34, 158.36,142.65, 135.83, 130.11, 128.03, 126.73, 126.54, 122.24, 121.28, 118.12,116.91, 114.95, 113.79, 113.69, 107.99, 42.18.

[0072] Compound YL26: yellow solid, 47% yield. 1H NMR (400MHz, DMSO) δ 8.62 (d, J = 10.3Hz, 2H), 8.02 (s, 1H), 7.87 (s, 1H), 7.79 (s, 1H), 7.59 (s, 1H), 7.46 (s,1H), 6.93 (s, 1H), 6.83 (d, J = 11.5 Hz, 2H), 6.76 (d, J = 15.9 Hz, 1H), 6.69 (s, 1H), 6.65 (d, J = 6.9 Hz, 2H), 6.59 (s, 1H), 4.23 (d, J = 5.9Hz, 2H). 13 C NMR(101MHz, DMSO-d6) 8 164.98, 142.71, 142.54, 139.45, 137.47, 136.73, 133.27,132.17, 131.92, 130.70, 128.05, 126.74, 126.62, 124.92, 122.28, 121.38,119.04, 116.88, 115.26, 114.96, 113.81, 112.64, 42.41.

[0073] Compound YL27: white solid, 40% yield. 1 H NMR (400MHz, DMSO) δ 8.72 (s, 1H), 8.64 (s, 1H), 7.89 (d, J = 8.3 Hz, 2H), 7.77 (d, J = 8.3 Hz, 2H), 7.55 (d, J= 15.8 Hz, 1H), 6.98 (s, 1H), 6.93 - 6.81 (m, 3H), 6.74 (s, 1H), 6.70 (d, J =7.8 Hz, 2H), 6.64 (s, 1H), 4.29 (d, J = 5.9 Hz, 2H). 13 C NMR (101MHz, DMSO-d6)8 164.89, 142.73, 142.54, 140.02, 139.36, 137.82, 133.37, 128.76, 128.05,126.74, 126.64, 125.93, 122.29, 121.39, 119.23, 116.90, 115.31, 114.97,113.81, 111.99, 42.44.

[0074] 2.2 In vitro antiferroptosis activity assay: The antiferroptosis activity of compounds YL6–YL27 was determined in an Erastin-induced HepG2 cell ferroptosis model. The results showed that the antiferroptosis activity of all substituent-modified compounds YL6–YL27 failed to surpass that of the parent compound YL1, as shown in Table 2. In terms of substituent type, compounds YL11–YL13 modified with phenolic hydroxyl groups (especially ortho-dihydroxyl groups) showed the best relative activity in this series, but their protective effect was still weaker than YL1; compounds YL6–YL10 and YL14–YL17 modified with electron-donating groups such as methyl and methoxy groups showed the next best activity; while compounds YL18–YL27 modified with electron-withdrawing groups such as fluorine, chlorine, and cyano groups showed significantly decreased activity, with cyano-substituted derivatives YL26–YL27 exhibiting the weakest activity.

[0075] After discussing the structure-activity relationships of compounds YL6–YL27, it was found that compounds modified with electron-donating groups generally exhibited better activity than those modified with electron-withdrawing groups, suggesting that an appropriate increase in the electron cloud density of the benzene ring may be beneficial to the interaction between the molecule and ferrodeath-related targets. Secondly, although phenolic hydroxyl groups can provide hydrogen bond donors, the substitution of polyphenolic hydroxyl groups did not further enhance the activity, indicating that the contribution of this group may be limited by the overall conformation of the molecule. Thirdly, the activity showed a decreasing trend with the increase of the number of substituents of the same type, indicating that the steric hindrance introduced by excessive substituents may interfere with target binding. Finally, the simple benzene ring structure of the parent compound YL1 may be the optimal configuration for this hybrid system, and additional substituents actually disrupted the steric fit required for the molecule to bind to the target.

[0076] 2.3 In vitro anti-inflammatory activity assay: The anti-inflammatory activity of these compounds was determined in an LPS-induced BV2 cell inflammation model. The results showed that the anti-inflammatory activity of all substituent-modified compounds failed to surpass that of the parent compound YL1, as shown in Table 2. In terms of substituent type, compounds with para-substitution (e.g., para-hydroxyl, para-fluorine) showed relatively better activity in this series, but were still weaker than YL1; compounds modified with electron-donating groups such as methoxy and methyl showed the next best activity; while compounds modified with electron-withdrawing groups such as chlorine and cyano showed the most significant decrease in activity.

[0077] 2.4 Structure-Activity Relationship Analysis: Based on the in vitro activity evaluation of the 22 substituent-modified compounds YL6–YL27, the following conclusions can be drawn: Regarding antiferroptosis activity, none of the modified compounds were superior to the parent compound YL1. The phenolic hydroxyl modifier showed the best activity, but was still weaker than YL1; electron-donating group (methyl, methoxy) modifiers were next; electron-withdrawing group (fluorine, chloro, cyano) modifiers showed significantly decreased activity, with the cyano derivative being the weakest. The anti-inflammatory activity showed a consistent trend: none of the modifiers exceeded YL1, with para-substituted compounds being relatively superior, and electron-donating group modifiers generally outperforming electron-withdrawing group modifiers. In summary, the substituents on the benzene ring of cinnamic acid failed to further enhance the dual pharmacological activity of YL1. The electron-donating group modifiers showed better activity than the electron-withdrawing group modifiers, suggesting that appropriately increasing the electron cloud density of the benzene ring may be beneficial to activity. However, the activity of all modifiers was inferior to that of the unsubstituted YL1, indicating that the simple benzene ring structure of cinnamic acid may be the optimal configuration in this phenothiazine hybrid system. Therefore, YL1 remains the compound with the best dual activity of antiferroptosis and anti-inflammation in this invention, and its structure will be further optimized using YL1 as the lead compound.

[0078] Table 2. Comparison of structure-activity relationships of compounds YL6–YL27 compound <![CDATA[EC 50 (μmol / L)]]> NO inhibition rate (%) compound <![CDATA[EC 50 (μmol / L)]]> NO inhibition rate (%) YL6 0.178±0.002 13.65±0.02 YL17 0.175±0.008 52.84±0.02 YL7 0.188±0.005 20.52±0.06 YL18 0.195±0.004 16.72±0.04 YL8 0.166±0.002 24.52±0.05 YL19 0.181±0.002 26.14±0.05 YL9 0.185±0.004 53.45±0.04 YL20 0.201±0.003 32.78±0.08 YL10 0.171±0.003 55.70±0.06 YL21 0.249±0.008 32.58±0.05 YL11 0.132±0.003 54.63±0.02 YL22 0.215±0.001 57.09±0.02 YL12 0.148±0.004 58.51±0.04 YL23 0.229±0.004 36.45±0.01 YL13 0.135±0.004 57.09±0.06 YL24 0.248±0.004 39.37±0.05 YL14 0.161±0.003 61.43±0.04 YL25 0.235±0.002 38.44±0.07 YL15 0.172±0.005 60.71±0.05 YL26 0.315±0.003 22.93±0.05 YL16 0.168±0.005 46.66±0.07 YL27 0.359±0.003 18.70±0.07 3. Optimization of the connection chain.

[0079] 3.1 Design and Synthesis of Target Compounds: Compound YL1, obtained by direct amide condensation of cinnamic acid and phenothiazine, showed the best performance in screening for dual anti-ferroptosis and anti-inflammatory activities and was identified as the lead compound. To further optimize the conformational flexibility and spatial adaptability of the molecules and enhance target affinity, this invention introduced different connecting chains between the cinnamic acid and phenothiazine skeletons of YL1, and systematically investigated the effects of their length, rigidity, and spatial orientation on dual activities. The connecting chain design included: a) cyclic connecting chains (quaternary, quinary, and septary rings) to explore the effects of ring strain and ring size on conformation, among which quinary rings are widely used due to their moderate ring strain and good biocompatibility; b) straight-chain connecting chains as a flexible control to evaluate the activity difference between rigid cyclic and flexible open-chain structures, in order to clarify the role of the combination of rigidity and flexibility in molecule-target interactions. Based on this, a total of 7 target compounds were designed and synthesized: LYL1 to LYL7.

[0080] .

[0081] Synthesis of compound LYL1: Step 1: Dissolve 2-cyanophithiazine (224.28 mg, 1.0 mmol) and lithium aluminum hydride (7.0 mmol) separately in anhydrous tetrahydrofuran. Add the former dropwise to the latter suspension with stirring and react at room temperature for 4 h. After the starting material is completely consumed, quench with water, extract with dichloromethane, combine the organic phases, wash with saturated brine, dry with anhydrous Na2SO4, filter, concentrate, and purify to obtain intermediate Y1 (2-aminomethylphenothiazine).

[0082] Step 2: Intermediate Y1 (228.31 mg, 1.0 mmol), trans-3-(tert-butoxycarbonylamino)cyclobutanecarboxylic acid (215.25 mg, 1.0 mmol), PyBOP (1.1 mmol), and DIPEA (2.0 mmol) were sequentially added to a dry reaction flask, dissolved in anhydrous DMF, and stirred at room temperature for 4 h. After the starting materials reacted completely, the mixture was extracted with dichloromethane / saturated brine. The organic phases were combined, dried over anhydrous Na2SO4, filtered, concentrated under reduced pressure, and purified to obtain compound LYL5a. The synthesis of LYL1a to LYL7a was similar, except that R in compound i was selected from -CH2-, -CH2-CH2-, -CH2-CH3-CH2-, ... , , or .

[0083] Step 3: Take compound LYL5a from Step 2, add cinnamic acid (1.0 mmol), PyBOP (1.1 mmol), and DIPEA (2.0 mmol), dissolve in 30 mL of anhydrous DMF, and stir at room temperature for 9 h. Extract the reaction solution with dichloromethane and distilled water, combine the organic phases, wash with 50 mL of saturated NaCl solution, dry to anhydrous Na2SO4, filter, and concentrate under reduced pressure. Purify the crude product by thin-layer chromatography (dichloromethane to methanol volume ratio 15:1) to obtain compound LYL5. Compounds LYL1 to LYL7 were prepared according to the same steps. The synthetic route of compound LYL5 is as follows:

[0084] .

[0085] Compound LYL1: white solid, 40% yield. 1H NMR (400MHz, DMSO) δ 8.64 (s, 1H), 8.41 (d, J = 8.9Hz, 2H), 7.58 (d, J= 7.0 Hz, 2H), 7.41 (t, J= 13.5 Hz, 4H), 6.98 (s, 1H), 6.87 (d, J = 18.7 Hz, 2H), 6.81- 6.59 (m, 5H), 4.16 (d, J =5.8Hz, 2H), 3.90 (d, J= 5.7 Hz, 2H), 3.05 (s, 2H). 13 C NMR(101MHz, DMSO-d6) 8169.28, 168.74, 142.55, 142.53, 139.44, 139.37, 135.38, 129.95, 129.41,128.01. 127.94, 126.65, 126.47, 122.57, 122.18, 121.29, 116.88. 115.13,114.94, 113.93, 42.73, 42.22.

[0086] Compound LYL2: brown solid, 49% yield. 1 H NMR (400MHz, DMSO) δ 8.59 (s, 1H),8.38 (s, 1H), 8.18 (s, 1H), 7.55 (d, J = 6.4 Hz, 2H), 7.48- 7.35 (m, 4H),6.98 (s, 1H), 6.89 (s, 1H), 6.81 (s, 1H), 6.74 (s, 1H), 6.68 (t, J = 11.9 Hz, 3H), 6.61 (s, 1H), 4.14 (d, J =5.9 Hz, 2H), 3.45 (d, J = 6.1 Hz, 2H), 2.46 -2.32 (m, 2H). 13 C NMR(101MHz, DMSO-d6) 8 170.84, 165.49, 142.51, 142.45,139.69, 139.07, 135.39, 129.86, 129.37, 128.64, 127.96.126.66, 126.43.122.71,122.19, 121.22, 116.87, 115.04, 114.88, 113.80.

[0087] Compound LYL3: yellow solid, 44% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (s, 1H), 8.35 (s, 1H). 8.25 (s, 1H), 7.51 (d, J= 6.8 Hz, 2H), 7.36 (dd, J = 21.2, 13.5Hz, 4H), 6.93 (s, 1H), 6.85 (s, 1H), 6.79 (s, 1H), 6.70 (d, J = 7.5 Hz, 2H), 6.61 (d, J = 15.8 Hz, 2H), 6.56 (s, 1H), 4.07 (d, J =5.9 Hz 2H), 3.13 (s,2H), 3.00-2.92(m, 1H), 2.15 (t, J = 7.5 Hz, 2H), 1.68 (d, J = 6.8 Hz2H). 13 CNMR(101MHz, DMSO-d6) δ 172.26, 165.53, 142.64, 142.59, 139.86, 139.06,135.41, 129.97, 129.48, 128.02, 126.74, 126.55.122.76, 122.26, 121.19,116.91, 114.97, 113.70, 49.13. 42.08, 33.36, 25.97.

[0088] Compound LYL4: a bright brown solid, 42% yield. 1 H NMR (400MHz, DMSO) δ 8.63 (s, 1H), 8.37 (s, 1H), 8.17 (s, 1H), 7.54 (s, 2H), 7.39 (dd, J = 17.9, 10.7 Hz, 4H), 6.97 (s, 1H), 6.88 (s, 1H), 6.74 (dd, J = 31.4, 10.3 Hz, 4H), 6.63 (d, J =9.8 Hz, 2H), 4.13 (d, J = 25.3 Hz, 2H), 3.05(s, 1H), 2.62 (s, 1H), 1.06 (t, J= 7.0 Hz, 3H). 13C NMR(101MHz, DMSO-d6) 8 174.66, 165.61, 142.46, 142.43,139.86, 139.06, 135.41, 129.35, 127.95, 126.64, 126.37, 122.76, 122.16,122.10, 116.85, 114.93, 114.87, 113.76, 42.64, 42.61, 42.02, 16.31.

[0089] Compound LYL5: white solid, 47% yield. 1 H NMR (400MHz, DMSO) δ 8.64 (s, 1H), 8.50 (d, J= 7.7 Hz, 1H), 8.27 (s, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.66 (d, J =8.8 Hz 2H), 7.55-7.48 (m, 3H). 6.93 (s, 1H), 6.84 (s, 1H), 6.80 (s, 1H), 6.68(d, J = 8.0 Hz, 2H), 6.63 -6.51 (m, 3H), 4.46 (s, 1H), 4.09 (d, J = 5.8 Hz, 2H), 2.38(s, 2H), 2.14(s, 2H), 1.67 (s, 1H). 13 C NMR (101MHz, DMSO-d6) 8174.93, 168.14, 164.57, 144.49, 142.59, 139.92, 139.29, 135.41.134.73,130.77, 129.43.128.74. 128.03, 127.83, 126.58, 125.02.122.60, 119.72, 114.97,113.78.42.58, 42.20, 33.60, 33.49.

[0090] Compound LYL6: Pink solid, 41% yield. 1H NMR (400MHz, DMSO) δ 8.69 (s, 1H),8.36 (s, 1H). 7.51 (d, J = 6.8 Hz, 2H), 7.36 (dd, J= 13.1, 5.4 Hz, 4H), 6.93(s, 1H), 6.84 (s, 1H), 6.79 (s, 1H), 6.68 (d, J = 7.9 Hz, 2H), 6.60 (d, J =15.6 Hz, 2H), 6.55 (s, 1H), 4.08 (d, J = 5.9 Hz, 2H), 2.68 (s, 1H), 2.07 (s,1H), 1.78 (s, 2H), 1.68 (s, 2H), 1.55 (d, J = 47.6 Hz, 2H). 13 C NMR (101MHz, DMSO-d6) δ 175.33, 164.87, 142.66, 142.62, 141.14, 139.88, 138.92, 135.49,134.12, 129.90, 129.46, 128.01, 126.72, 126.57, 122.92, 122.23, 121.14,116.88, 114.98, 113.71, 50.89, 46.36, 43.07, 42.20, 32.74, 28.16.

[0091] Compound LYL7: brown solid, 45% yield. 1 H NMR (400MHz, DMSO)δ 8.60 (s, 1H),8.28.(s, 1H), 8.15 (s, 1H), 7.51 (d, J=5.6 Hz, 2H), 7.40→7.33 (m, 4H), 6.93(s, 1H), 6.85 (s, 1H), 6.80 (s, 1H), 6.70 (s, 1H), 6.66 (s, 1H), 6.62 →6.52(m, 3H), 4.20 (s, 1H), 4.07 (s, 2H), 3.33 (s, 2H), 2.78.(s, 1H), 1.93 (d, J=14.9 Hz, 2H), 1.67 (d, J= 5.2 Hz, 2H), 1.45 (s, 1H), 1.18 (s, 1H). 13C NMR(101MHz, DMSO-d6)-8 175.34, 164.86, 142.62, 142.57, 139.99, 138.91, 135.47,129.91, 129.47, 128.02, 127.96, 126.73, 126.56, 122.84, 121.20, 116.90,115.01, 114.94, 113.72, 50.98, 42.75, 42.16, 32.84, 28.65.

[0092] 3.2 In vitro ferroptosis activity assay: The ferroptosis activity of compounds LYL1–LYL7 was determined in an Erastin-induced HepG2 cell ferroptosis model. The results showed that compounds LYL5–LYL7 with introduced cyclic linkers exhibited superior ferroptosis activity compared to the parent compound YL1, while compounds LYL1–LYL4 with introduced straight-chain linkers showed slightly lower ferroptosis activity. The ferroptosis activity of compounds LYL5–LYL7 modified with different cyclic linkers was significantly enhanced, with LYL7 modified with a six-membered ring linker showing the most prominent activity. These results indicate that the structural characteristics of the linker significantly affect the molecular ferroptosis activity. The introduction of cyclic linkers may constrain the molecular conformation and reduce flexibility, allowing the cinnamic acid and phenothiazine pharmacophores to present a more favorable three-dimensional configuration for binding to ferroptosis-related targets. Conversely, flexible straight-chain linkers, due to their greater conformational freedom, may lead to a decrease in the proportion of active conformations, thus affecting efficacy. Furthermore, different ring sizes have varying effects on activity, with the six-membered ring showing the best performance, suggesting that this ring size has the best spatial fit in this hybrid system.

[0093] 3.3 In vitro anti-inflammatory activity assay: The anti-inflammatory activities of compounds LYL1–LYL7 were measured in an LPS-induced BV2 cell inflammation model. The results showed that LYL7, with a six-membered ring linker, exhibited superior anti-inflammatory activity compared to its parent compound YL1, demonstrating the strongest NO inhibition. The anti-inflammatory activity of LYL6, modified with a five-membered ring linker, was slightly lower than that of YL1. However, the anti-inflammatory activity of LYL5, modified with a four-membered ring linker and a straight-chain linker, was significantly reduced, and its NO inhibition rate was noticeably weakened. These results indicate that the structural characteristics of the linker have different effects on anti-inflammatory activity than on anti-ferroptosis activity. The six-membered ring linker performed best in this series, suggesting that its ring size may be more conducive to spatial matching between the molecule and inflammation-related targets. The five-membered ring was slightly inferior to the six-membered ring in anti-inflammatory activity, indicating that the molecular conformation requirements for different pharmacological activities may differ. The four-membered ring, due to its higher ring strain, may limit conformational flexibility, while the straight-chain linker, due to excessive flexibility, leads to a lower proportion of active conformations; both are detrimental to the exertion of anti-inflammatory activity.

[0094] 3.4 Structure-Activity Relationship Analysis: Based on the in vitro activity evaluation results of the seven linked chain modified target compounds LYL1–LYL7, the following conclusions can be drawn: In terms of antiferroptosis activity, compounds LYL5–LYL7 with introduced cyclic linked chains showed superior activity compared to the parent compound YL1, with LYL7 exhibiting the most outstanding performance from the six-membered ring linked chain; while compounds LYL1–LYL4 with straight-chain linked chains showed slightly lower activity than YL1. In terms of anti-inflammatory activity, compound LYL7 with a six-membered ring linked chain showed superior activity compared to YL1, exhibiting the strongest NO inhibition; compound LYL6 with a five-membered ring linked chain showed slightly lower activity than YL1; and compounds LYL1–LYL5 with four-membered ring and straight-chain linked chains showed significantly reduced activity. These results indicate that the structural characteristics of the linked chain have a significant impact on dual activity. Cyclic linkers, due to their conformational constraints, allow the cinnamic acid and phenothiazine pharmacophores to present more favorable three-dimensional configurations, thereby enhancing target affinity; while linear linkers, due to their excessive flexibility, may lead to a decrease in the proportion of active conformations. Different ring sizes contribute differently to the two activities: the six-membered ring shows the best performance in antiferroptosis and anti-inflammatory screening. In summary, the introduction of cyclic linkers can significantly enhance the antiferroptosis and anti-inflammatory activities of compounds, with the six-membered ring showing the most significant effect. The general structural formula of the cinnamic acid derivative is:

[0095] R is a C1-C3 alkyl group or a C4-C6 cycloalkyl group.

[0096] Table 3. Comparison of structure-activity relationships of compounds LYL1 to LYL7 compound <![CDATA[EC 50 (μmol / L)]]> NO inhibition rate (%) compound <![CDATA[EC 50 (μmol / L)]]> NO inhibition rate (%) LYL1 0.061±0.005 34.13±0.06 LYL5 0.046±0.005 45.44±0.05 LYL2 0.064±0.003 32.78±0.05 LYL6 0.059±0.004 65.70±0.04 LYL3 0.061±0.006 37.36±0.05 LYL7 0.018±0.003 80.66±0.02 LYL4 0.061±0.003 42.90±0.03 / / / 4. Taking compound LYL7 as an example, we conducted an in vitro study on the mechanism of cinnamic acid derivatives.

[0097] 4.1 Compound LYL7 is a free radical scavenger that does not chelate Fe. 2+ .

[0098] To investigate the antioxidant mechanism of compound LYL7 and its potential target in the ferroptosis pathway, this invention first used a DPPH radical scavenging assay to evaluate its ability to directly scavenge free radicals. The experiment included a solvent group (DMSO group), a ferroptosis positive control group (Fer-1 group), an intermediate product group (Y1 group), a raw material group (cinnamic acid group), and an experimental group (LYL7 group). The results showed that LYL7 exhibited significant concentration-dependent free radical scavenging activity, such as… Figure 2 In the same experimental conditions, its antioxidant efficacy was superior to that of intermediate Y1, indicating that the introduction of the cinnamic acid structural fragment enhanced the electron delocalization ability of the parent nucleus or provided additional active sites, thereby improving the antioxidant efficacy. Compared with the ferroptosis positive control group (Fer-1 group), the free radical scavenging ability of LYL7 was slightly weaker than that of Fer-1. Furthermore, the raw material cinnamic acid showed almost no DPPH scavenging activity within the tested concentration range, further confirming that the phenothiazine skeleton is the core structural unit for the antioxidant function of this compound.

[0099] Given that the mechanism of action of some ferroptosis inhibitors is related to iron ion chelation, this invention investigated the interaction between LYL7 and Fe through iron chelation experiments. 2+ The binding capacity of ferrophosphate was investigated. The experiment included a solvent group (DMSO group), a negative control group (H2O2 group), an iron chelation positive control group (EDTA group and DFS group), a ferroptosis positive control group (Fer-1 group), a raw material group (cinnamic acid group), and an experimental group (LYL7 group). The results showed that at the detected concentration, LYL7 did not exhibit significant Fe binding capacity. 2+ The chelation effect showed no significant difference in its UV-Vis absorption spectrum compared to the negative control group (H2O2 group). Figure 2 In the B group, the ferroptosis positive control group (Fer-1 group), a classic inhibitor of the ferroptosis pathway, also showed no detectable iron chelating ability. However, known iron chelating agents ethylenediaminetetraacetic acid (EDTA) and deferoxamine (DFS) both exhibited strong iron chelating activity in this experimental system, verifying the reliability of the experimental system. This indicates that the antioxidant activity of compound LYL7 mainly stems from its ability to directly scavenge free radicals as a free radical scavenger, rather than through chelating Fe. 2+ It inhibits iron-dependent lipid peroxidation. This characteristic suggests that LYL7 may exert its protective effect against ferroptosis primarily by disrupting free radical chain reactions.

[0100] 4.2 Compound LYL7 inhibits Erastin-induced ferroptosis in HepG2 cells.

[0101] 4.2.1 Compound LYL7 restores antioxidant reserves and inhibits lipid peroxidation in an Erastin-induced HepG2 cell ferroptosis model. To verify the regulatory effect of compound LYL7 on ferroptosis at the cellular level, this invention used an Erastin-induced HepG2 cell ferroptosis model, and detected the content of malondialdehyde (MDA), the end product of lipid peroxidation, the level of intracellular reduced glutathione (GSH), and the accumulation of reactive oxygen species (ROS) to evaluate the ability of LYL7 to restore cellular redox homeostasis. Control group, Erastin (20 μM) group, Erastin (20 μM) + DMSO group, Erastin (20 μM) + Fer-1 (1 μM) group, and Erastin (20 μM) + LYL7 (1 μM) group were set up, as follows: Figure 3 and Figure 4 The results showed that, compared with the control group, the MDA level of HepG2 cells in the Erastin (20 μM) group was significantly increased, indicating that the ferroptosis inducer successfully induced lipid peroxidation damage. In the Erastin (5 μM) + LYL7 (1 μM) group, the MDA content decreased in a concentration-dependent manner, indicating that LYL7 could effectively inhibit Erastin-induced lipid peroxidation. Simultaneously, intracellular GSH levels were significantly depleted after Erastin stimulation, reflecting damage to the cellular antioxidant defense system; while LYL7 treatment significantly reversed the downward trend of GSH, suggesting that it helps restore the cellular endogenous antioxidant reserves. Detection of intracellular ROS levels using fluorescent probes revealed that Erastin treatment led to a significant increase in ROS fluorescence intensity in HepG2 cells, indicating that oxidative stress was activated. Compared with the model group, the ROS fluorescence intensity in the LYL7 intervention group was significantly reduced, confirming that LYL7 has the ability to scavenge excess ROS, thereby alleviating oxidative stress damage. In summary, LYL7 can protect against ferroptosis in Erastin-induced HepG2 cell ferroptosis by increasing GSH levels, decreasing MDA and ROS levels, restoring the cell's antioxidant defense function, and inhibiting lipid peroxidation.

[0102] 4.2.2 Compound LYL7 reduces iron overload in an Erastin-induced HepG2 cell ferroptosis model. 2+ It plays a key role in catalyzing lipid peroxidation during ferroptosis. To further explore the possible mechanism by which LYL7 intervenes in ferroptosis, this invention uses an Erastin-induced HepG2 cell ferroptosis model to detect intracellular Fe. 2+Changes in levels. Four groups were established: a control group (Control group), an Erastin (20 μM) group, an Erastin (20 μM) + DMSO group, an Erastin (20 μM) + Fer-1 (1 μM) group, and an Erastin (20 μM) + LYL7 (1 μM) group. The results showed that, compared with the control group (Control group), the Erastin (20 μM) group had significantly lower levels of Fe in HepG2 cells. 2+ The significantly elevated levels indicate that the ferroptosis inducer successfully triggered an imbalance of intracellular iron homeostasis and iron overload, such as Figure 5 This result is consistent with Erastin's inhibition of the cystine / glutamate antitransporter (System X). c - This is consistent with existing reports of indirect effects on iron metabolism pathways. After intervention with different concentrations of LYL7, intracellular Fe... 2+ The levels showed a significant concentration-dependent decrease. Compared with the Erastin (20 μM) group, the Fe levels in Erastin (20 μM) + LYL7 (1 μM) cells were significantly lower. 2+ The significantly reduced iron content suggests that LYL7 can effectively alleviate Erastin-induced intracellular iron overload. Combined with previous in vitro chemical experiments that revealed LYL7 does not directly possess Fe... 2+ Based on the chelating ability results, it is speculated that LYL7 reduces Fe at the cellular level. 2+ Its effect does not stem from direct binding of iron ions. In summary, LYL7 can significantly reduce Fe in the Erastin-induced HepG2 cell ferroptosis model. 2+ It restores intracellular iron homeostasis. This effect, along with its ability to inhibit lipid peroxidation and restore antioxidant reserves, constitutes its multiple mechanisms for combating ferroptosis.

[0103] 42.3 Compound LYL7 upregulates GPX4 expression in an Erastin-induced HepG2 cell ferroptosis model but does not affect xCT levels. To elucidate the molecular mechanism by which LYL7 intervenes in ferroptosis, this invention used Western blotting to detect the protein expression levels of the key ferroptosis regulator GPX4 and the systemic Xc-functional subunit xCT, in order to explore the target of LYL7. Figure 6The results showed that in the Erastin-induced ferroptosis model of HepG2 cells, the expression level of GPX4 protein was significantly lower than that of the normal control group, indicating that the ferroptosis process is accompanied by the depletion of GPX4. After intervention with LYL7, the expression of GPX4 rebounded in a concentration-dependent manner, and at high concentrations, its upregulation was greater than that of the positive control drug Fer-1, suggesting that LYL7 has a better efficacy in restoring GPX4 protein levels. Given that GPX4 is a core enzyme in scavenging lipid peroxides, this result is highly consistent with the aforementioned cellular phenotype of LYL7 reducing MDA and ROS, further confirming that LYL7 inhibits lipid peroxidation by maintaining GPX4 expression. However, the detection results of xCT protein showed a different regulatory pattern. Erastin treatment significantly reduced the expression level of xCT in HepG2 cells. Contrary to expectations, LYL7 intervention failed to reverse the Erastin-induced downregulation of xCT protein, and there was no statistically significant difference in xCT levels between the treatment groups and the model group. This result indicates that the effect of LYL7 in restoring intracellular GSH levels is not achieved by upregulating xCT expression. In summary, LYL7 selectively upregulates GPX4 expression in the Erastin-induced ferroptosis model without significantly affecting xCT levels. Combined with previous findings that LYL7 increases GSH but lacks iron-chelating activity in vitro, it is speculated that LYL7 may indirectly maintain the function of the glutathione system by protecting GPX4 protein stability or promoting its post-translational regulation, independent of activation of the Xc- pathway. This selective action on key regulatory nodes of ferroptosis provides a new perspective for understanding the anti-ferroptosis mechanism of LYL7.

[0104] 4.3 Compound LYL7 inhibits the release of inflammatory factors in an LPS-induced BV2 cell inflammation model. To further investigate the anti-inflammatory activity of the target compound LYL7, this experiment used a lipopolysaccharide (LPS)-stimulated microglial BV2 cell inflammation model. The secretion levels of key pro-inflammatory factors interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in the cell supernatant were detected by ELISA to assess the regulatory role of LYL7 in the inflammatory response. Experimental data showed that compared with the normal control group, after 24 hours of LPS stimulation alone, the levels of IL-6, IL-1β, and TNF-α in the BV2 cell supernatant were significantly increased, indicating the successful establishment of the inflammation model. After intervention with different concentrations of LYL7, the release of the above three inflammatory factors decreased in a concentration-dependent manner, suggesting that LYL7 can effectively inhibit LPS-induced excessive activation of microglia and the secretion of pro-inflammatory factors, such as... Figure 7 .

[0105] In a cross-sectional comparison of anti-inflammatory efficacy, LYL7 demonstrated superior potential compared to several positive control drugs. Under the same experimental conditions, LYL7 showed stronger inhibitory effects on IL-6, IL-1β, and TNF-α than the positive control drugs methylene blue and NAC, as well as the precursor cinnamic acid. This result indicates that by molecularly hybridizing the phenothiazine skeleton with cinnamic acid derivatives, LYL7 achieves superior inflammatory regulatory activity while retaining the anti-inflammatory potential of its parent nucleus. Its mechanism of action may differ from simple antioxidant effects or the effects derived from the parent nucleus structure.

[0106] In summary, LYL7 significantly inhibited the release of IL-6, IL-1β, and TNF-α in an LPS-induced BV2 cell inflammation model, demonstrating superior anti-inflammatory activity compared to methylene blue, NAC, and cinnamic acid. This finding, along with previous findings on the role of LYL7 in restoring antioxidant reserves in a ferroptosis model, suggests a multi-target mechanism by which LYL7 regulates the oxidative-inflammatory network.

[0107] 5. Evaluation of the in vivo therapeutic effect of compound LYL7.

[0108] 5.1 Compound LYL7 alleviates APAP-induced acute liver injury in mice. To investigate the protective effect of LYL7 against APAP-induced acute liver injury, this invention established a mouse model of acute liver injury induced by acetaminophen, and intervened by administering LYL7, the positive control drug Fer-1 (ferstatin-1), and NAC (N-acetylcysteine), respectively. The in vivo therapeutic effect of LYL7 was evaluated by detecting serum liver function biochemical indicators and observing liver histopathological changes.

[0109] The results showed that, compared with the normal control group, the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities in the model group mice were significantly increased, indicating that APAP successfully induced acute liver injury in mice and the model was successfully established. Figure 8 and Figure 9Compared with the model group, the serum transaminase levels of mice in each group treated with different drugs showed varying degrees of decline. Notably, the serum GPT and GOT levels in the LYL7 intervention group were not only significantly lower than those in the model group, but also significantly lower than those in the Fer-1 and NAC intervention groups, demonstrating a superior transaminase-lowering effect. Further observation of liver tissue HE staining pathological sections confirmed the biochemical indicators. Under a 10x optical microscope, the normal control group mice showed clear liver lobule structures, neatly arranged hepatocyte cords, and uniform hepatocyte morphology without obvious abnormalities. The livers of the APAP model group mice exhibited severe pathological damage, with large areas of hepatocyte necrosis, loss of disordered hepatocyte cord structure, destruction of normal liver tissue structure, and significant inflammatory cell infiltration. In contrast, the liver pathological damage in the Fer-1 and NAC intervention groups was improved to some extent, with a reduction in the area of ​​hepatocyte necrosis and a decrease in tissue structural damage. In the LYL7 intervention group, the pathological damage to the mouse liver was significantly alleviated, the liver lobule structure was relatively intact, the hepatocytes were arranged more neatly, and only a small number of scattered hepatocyte swellings or punctate necrosis were observed. The necrotic area and the degree of inflammatory infiltration were significantly less than those in the two positive drug control groups.

[0110] In summary, under the experimental conditions, compound LYL7 effectively reduced serum transaminase levels in mice with APAP-induced acute liver injury and significantly improved pathological changes in liver tissue. Its therapeutic effect in this experiment was superior to the classic anti-ferroptosis drug Fer-1 and the first-line clinical drug N-acetylcysteine, suggesting that LYL7 has good application potential in the treatment of APAP-induced acute liver injury.

[0111] 5.2 Compound LYL7 inhibits APAP-induced ferroptosis in vivo. To investigate whether the protective effect of compound LYL7 against APAP-induced acute liver injury is related to its inhibition of ferroptosis, this invention further examined biochemical indicators closely related to ferroptosis in mouse liver tissue. The results showed that, compared with the normal control group, the MDA content in the liver tissue of the APAP model group mice was significantly increased, the GSH level was significantly decreased, and the Fe content was significantly reduced. 2+ The significantly increased levels indicate that typical ferroptosis-related events, such as lipid peroxidation accumulation, decreased antioxidant capacity, and iron metabolism disorders, occurred during APAP-induced acute liver injury. After intervention with different drugs, the above indicators all showed varying degrees of improvement, such as... Figure 10 Compared with the model group, the MDA content in the liver tissue of mice in the LYL7 intervention group was significantly reduced, while the GSH level was significantly increased, and the Fe content was significantly reduced. 2+ The content also decreased significantly. Notably, compared to the classic ferroptosis inhibitor Fer-1, compound LYL7 significantly reduced MDA and Fe content.2+ The compound LYL7 showed stronger effects in terms of both content and GSH level enhancement, with statistically significant differences. These results indicate that LYL7 can effectively inhibit APAP-induced lipid peroxidation in liver tissue, restore antioxidant capacity, and regulate iron ion homeostasis, suggesting that it can inhibit ferroptosis in vivo.

[0112] 5.3 Compound LYL7 inhibits APAP-induced inflammation in vivo.

[0113] To further investigate whether the protective effect of compound LYL7 against APAP-induced acute liver injury is related to its anti-inflammatory activity, this invention used ELISA to detect the levels of key inflammatory factors IL-6, IL-1β, and TNF-α in mouse liver tissue. Figure 11 The results showed that, compared with the normal control group, the levels of IL-6, IL-1β, and TNF-α in the APAP model group mice were significantly increased, indicating that APAP stimulation triggered a strong inflammatory response and a large release of various pro-inflammatory factors. After intervention with different drugs, the expression levels of the above inflammatory factors showed varying degrees of decline. Compared with the model group, the levels of IL-6, IL-1β, and TNF-α in the LYL7 intervention group mice were significantly reduced, indicating that LYL7 can effectively inhibit the APAP-induced inflammatory response. Furthermore, compared with the first-line clinical drug N-acetylcysteine, LYL7 showed a more significant effect in reducing the levels of these three inflammatory factors, and its inhibitory effect was significantly better than that of the NAC group, with statistically significant differences. These results indicate that LYL7 can effectively inhibit the release of APAP-induced inflammatory factors and exhibits good anti-inflammatory activity in vivo.

[0114] 6. Drug safety evaluation.

[0115] 6.1 Compound LYL7 showed no significant cytotoxicity in various cell lines in vitro. To assess the biosafety of compound LYL7, this invention first tested its in vitro cytotoxicity in different cell types. The selected cell lines included both normal cells that might be involved in subsequent pharmacological experiments and various tumor cell lines to comprehensively observe the selective effects of the compound. Figure 12The results showed that in normal cell models, treatment with compound LYL7 on human renal cortical proximal tubular epithelial HK-2 cells, normal human liver L02 cells, and normal human pancreatic HPNE cells did not significantly decrease the relative cell viability compared to the control group within the concentration range of 0–60 μM. Simultaneously, in tumor cell models, including human hepatocellular carcinoma HepG2 cells, mouse microglioma BV2 cells, human colorectal carcinoma HCT116 cells, human colorectal carcinoma RKO cells, and rat adrenal pheochromocytoma PC12 cells, compound LYL7 also did not exhibit significant proliferation inhibition or toxicity within the same concentration range.

[0116] The above results indicate that, at concentrations up to 60 μmol / L, compound LYL7 did not produce significant cytotoxicity against the various normal and tumor cell lines, suggesting that it has good in vitro safety within this dosage range.

[0117] 6.2 Compound LYL7 showed no significant acute toxicity in mice.

[0118] 6.2.1 Compound LYL7 had no significant effect on the general behavior and body weight of mice. To assess the preliminary safety of compound LYL7 in vivo and provide in vivo evidence for its pharmacodynamic studies in an acute liver injury model, this invention conducted a continuous administration toxicity observation on Balb / c mice. The experiment included a control group, a low-dose group (100 mg / kg), and a high-dose group (250 mg / kg), administered via tail vein injection once daily for 16 consecutive days. During the administration period, the general condition of the mice was dynamically monitored, including behavioral activity, mental state, food and water intake, coat color, and any abnormal reactions, and body weight was measured periodically. Figure 13 The experimental results showed that during the entire 16-day administration period, the general behavior of mice in each administration group was not significantly abnormal compared to the control group. Mice were active and responsive, with normal food and water intake, smooth fur, and no signs of toxicity such as diarrhea, convulsions, or death. Weight monitoring data showed that the weight gain trends of mice in the low-dose and high-dose groups were basically consistent with the control group, and there were no statistically significant differences in weight between the groups at any time point. These results indicate that after 16 consecutive days of administration, compound LYL7 at doses of 100 mg / kg and 250 mg / kg did not significantly affect the general condition and weight gain of Balb / c mice, suggesting that the compound has good in vivo tolerability within this dose range.

[0119] 6.2.2 Compound LYL7 did not cause liver and kidney damage in mice. Based on a 16-day observation period after administration, the levels of liver-related enzymes and kidney-related metabolites in the serum of mice in each group were measured to assess the potential effects of compound LYL7 on the liver and kidneys. Figure 14 The results showed that, compared with the control group, the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities in mice treated with low-dose (100 mg / kg) and high-dose (250 mg / kg) LYL7 were not significantly increased, indicating that the compound did not cause hepatocellular damage. Meanwhile, the serum creatinine and blood urea nitrogen levels, reflecting glomerular filtration function, remained at comparable levels in all treatment groups compared with the control group, with no statistically significant differences. These biochemical results were consistent with previously observed trends in mouse behavior and weight changes, further confirming that continuous administration of LYL7 at doses of 100 mg / kg and 250 mg / kg for 16 days did not cause significant liver and kidney damage in Balb / c mice.

[0120] 6.2.3 Compound LYL7 did not cause any histopathological damage to the major organs of mice.

[0121] Based on the aforementioned 16-day continuous drug administration observation and serum biochemical tests, this invention further performed histopathological examinations on the major organs of mice in each group to assess whether compound LYL7 caused substantial damage. After the last administration, the heart, liver, spleen, lungs, and kidneys of mice in the control group, low-dose group (100 mg / kg), and high-dose group (250 mg / kg) were taken, embedded in paraffin, sectioned, stained with hematoxylin and eosin, and observed under a light microscope for morphological changes.

[0122] like Figure 15 Histopathological results showed that the organs of the control group mice had clear structures, normal cell morphology, and no obvious lesions. Compared with the control group, the myocardial fibers of the mice in the low-dose and high-dose LYL7-treated groups were neatly arranged, the liver lobule structure was intact, the hepatocyte cords were arranged in an orderly manner, and no necrosis or inflammatory cell infiltration was observed. The red and white pulp boundaries of the spleen were clear, the alveolar structure was intact, and the septa were not thickened. The glomeruli and renal tubules had normal morphology and no abnormal changes in the interstitium. The above observations indicate that continuous administration of compound LYL7 at doses of 100 mg / kg and 250 mg / kg for 16 days did not cause significant histopathological damage to the major organs of Balb / c mice.

[0123] Based on general behavioral observations, weight monitoring, serum liver and kidney function indicators, and the results of this histopathological examination, it can be concluded that compound LYL7 has good in vivo safety in the dose range of 100 mg / kg and 250 mg / kg, which provides a reliable toxicological basis for its subsequent application in studies of acetaminophen-induced acute liver injury.

[0124] The above are merely preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A cinnamic acid derivative, characterized in that, The general structural formula of the cinnamic acid derivative is as follows: ; Wherein, R is a C1-C3 alkyl group or a C4-C6 cycloalkyl group.

2. The cinnamic acid derivative according to claim 1, characterized in that, The cinnamic acid derivative is any one of the following compounds: 。 3. A method for preparing the cinnamic acid derivative according to claim 1 or 2, characterized in that, Includes the following steps: Compound ii was prepared by amidation of compound i with 2-aminomethylphenthiazide in an organic solvent in the presence of a phosphorus salt coupling agent and an organic base. Compound ii was reacted with cinnamic acid in an organic solvent in the presence of a phosphorus salt coupling agent and an organic base to prepare a cinnamic acid derivative; the chemical reaction formula is as follows: 。 4. The method for preparing the cinnamic acid derivative according to claim 3, characterized in that, In the preparation of compound ii, the molar ratio of 2-aminomethylphenthiazide to compound i is 1 to 1.3:1; the molar ratio of compound i to the phosphonium salt coupling reagent and the organic base is 1:1 to 1.1:1.5 to 2. In the preparation of cinnamic acid derivatives, the molar ratio of compound i to cinnamic acid is 1:1; the molar ratio of cinnamic acid to the phosphorus salt coupling reagent and the organic base is 1:1 to 1.1:1.5 to 2. The phosphorus salt coupling reagent is benzotriazol-1-yl-oxytripyrrolylphosphine hexafluorophosphate; the organic base is N,N-diisopropylethylamine; and the organic solvent is N,N-dimethylformamide.

5. The use of a cinnamic acid derivative or a pharmaceutically acceptable salt thereof as described in claim 1 or 2 in the preparation of a medicament, characterized in that, The drug is used to prevent or treat acute liver injury.

6. The application according to claim 5, characterized in that, The drug is used to intervene in any one or more of the oxidative damage, ferroptosis, and inflammatory pathways.

7. The application according to claim 6, characterized in that, The drug is used to improve acetaminophen-induced oxidative damage and inflammatory pathways.

8. The application according to claim 7, characterized in that, The drug is used to inhibit the secretion of interleukin-6, interleukin-1β, and tumor necrosis factor-α in the acetaminophen-induced inflammatory pathway.

9. The application according to claim 6, characterized in that, The drug is used to inhibit Erastin-induced ferroptosis.

10. The application according to claim 9, characterized in that, The drug inhibits Erastin-induced ferroptosis in HepG2 cells by upregulating GPX4 expression.